key: cord-0982705-ttfukeue
authors: Ji, Dong; Zhang, Dawei; Xu, Jing; Chen, Zhu; Yang, Tieniu; Zhao, Peng; Chen, Guofeng; Cheng, Gregory; Wang, Yudong; Bi, Jingfeng; Tan, Lin; Lau, George; Qin, Enqiang
title: Prediction for Progression Risk in Patients with COVID-19 Pneumonia: the CALL Score
date: 2020-04-09
journal: Clin Infect Dis
DOI: 10.1093/cid/ciaa414
sha: 231730d5088bfae47ac8e84c4011bf66af782f61
doc_id: 982705
cord_uid: ttfukeue

BACKGROUND: We aimed to clarify the high-risk factors with multivariate analysis and establish a prediction of disease progression, so as to help clinicians to better choose therapeutic strategy. METHODS: All the consecutive patients with COVID-19 admitted to Fuyang second people’s hospital or the fifth medical center of Chinese PLA general hospital between January 20 and February 22, 2020, were enrolled and their clinical data were retrospectively collected. Multivariate COX regression was used to identify the risk factors associated with progression, and then were incorporated into the nomogram to establish a novel prediction scoring model. ROC was used to assess the performance of the novel model. RESULTS: Overall, 208 patients were divided into stable group (n=168, 80.8%) and progressive group (n=40,19.2%) based on whether their conditions worsened during the hospitalization Univariate and multivariate analysis showed that comorbidity, older age, lower lymphocyte and higher lactate dehydrogenase at presentation were independent high-risk factors for COVID-19 progression. Incorporating these 4 factors, the nomogram achieved good concordance indexes of 0.86 (95%CI 0.81 - 0.91), and had well-fitted calibration curves. A novel scoring model, named as CALL, was established, and its area under ROC was 0.91 (95% CI 0.86 to 0.94). Using a cutoff value of 6 points, the positive and negative predictive values were 50.7% (38.9% - 62.4%) and 98.5% (94.7% - 99.8%), respectively. CONCLUSION: Using the CALL score model, clinicians can improve the therapeutic effect and reduce the mortality of COVID-19 with more accurate and reasonable resolutions on medical resources.

A c c e p t e d M a n u s c r i p t

The outbreak of coronavirus disease 2019 (COVID-19) due to SARS-CoV-2 infection has influenced all provinces of China and spread to over 180 countries worldwide since January 2020 [1] . The number of new and severe cases have been increasing rapidly daily due to the easy transmissibility of the virus by patients with only mild illness or asymptomatic carriers [2] . Many countries have made emergency responses and adopted strict measures like locking down cities or regions. The world Health Organization (WHO) had declared COVID-19 a pandemic on March 11, 2020 [3] . The large number of infected persons result in tremendous unmet medical demands and unresolved personal protective equipment shortage in many countries.

With increasing case numbers and clinical experiences, more and more detailed information about COVID-19 pneumonia has been revealed. Huang et al [4] first reported clinical manifestations of 41 patients infected with SARS-CoV-2 and observed that ICU patients had higher plasma levels of cytokines compared with non-ICU patients. Chen et al [5] found that the infection more likely affected older males with comorbidities. Wang et al [6] compared clinical parameters of severe and non-severe cases in 138 hospitalized patients. Again, patients who required ICU care were significantly older and more likely to have underlying comorbidities, such as hypertension, diabetes, cardiovascular disease and cerebrovascular disease. However, all above studies were single center and univariate analysis-based studies without considering the influence of confounding factors because of small sample sizes. Therefore, clarifying the independent high-risk factors with multivariate analysis and establishing an accurate prediction of progression of COVID-19 become desirable. In the present study, we used COX proportional regression and nomogram to provide an evidence-based, factors-weighted, highly accurate risk estimation model to help clinicians to better choose therapeutic strategy. To our knowledge, this scoring prediction model is the first nomogram for progressive risk estimation in patients with COVID-19.

A c c e p t e d M a n u s c r i p t

This study was approved by both the Ethics Committees of Fuyang Second People's Hospital (FYSPH), Anhui (20200303006) and the fifth medical center of Chinese PLA general hospital (PLAGH), Beijing (2020005D). Written informed consent was waived in view of the designated hospital for new emerging infectious diseases. Both FYSPH in Anhui Province and the fifth medical center of PLAGH in Beijing (center two) were assigned as COVID-19 treatment center on January 20, 2020. Patients presenting with severe COVID-19 were excluded. For this retrospective, non-interventional study, we enrolled all patients with confirmed COVID-19 admitted to either of the two centers since January 20, 2020. COVID-19 was diagnosed based on the WHO interim guidance [7] and guidance for corona virus disease 2019 issued by National Health Commission of China [8] . The presence of SARS-CoV-2 in respiratory specimens was confirmed using real-time reverse-transcriptase polymerase chain reaction (RT-PCR) assay by local district level and municipal Center for Diseases Prevention and Control (CDC), as described previously [4] . The exclusion criteria were primary infection by other pathogens, such as bacteria, fungi, other respiratory virus, mycoplasma, or chlamydia. Comorbidity was defined as having at least one of the followings: hypertension, diabetes, cardiovascular disease, liver disease, asthma, chronic lung disease, HIV infections and malignancy for at least 6 months. Severe COVID-19 was defined as at least one of the followings, respiratory rate ≥ 30 breaths/min, resting oxygen saturation ≤ 93%, PaO2/FiO2 ≤ 300 mmHg or requirement of mechanical ventilation. Progression to severe COVID-19 was development of one or more of the above or worsening of lung CT findings during the observation period. 

After admission to the two centers, the presenting history, comorbidity status, epidemiologic history, and vital signs of patients were collected. Comorbidity was defined as having at least one of the followings: hypertension, diabetes, cardiovascular disease, liver disease, asthma, chronic lung disease, HIV infections and malignancy for at least 6 months. The laboratory parameters, including complete blood count, coagulation profile, liver and renal function, lactate dehydrogenase (LDH) and procalcitonin (PCT) were examined at admission. The O2 saturation was measured by pulse oxygen saturation on room air at rest state and confirmed by blood gas test. Respiratory specimens, including nasal and pharyngeal swabs, or sputum were tested for influenza, avian influenza, respiratory syncytial virus, adenovirus, parainfluenza virus using real-time RT-PCR assays approved by the China Food and Drug Administration. CURB-65 severity score [9] was calculated for each subject. All patients were examined by chest X-ray or CT scan. Clinical outcomes (progression of illness, days to progression, mortality, discharges, and length of hospital stay) were monitored up to March 18, 2020. The date in source documents were confirmed independently by at least two researchers.

Continuous variables of normal distribution were expressed as mean ± SD and compared using the unpaired, 2-tailed student's t test. Continuous variables of skewed distribution were showed as median [interquartile range A c c e p t e d M a n u s c r i p t (IQR)] and compared with Mann-Whitney test. Categorical variables were presented as numbers (percentage) and compared by the chi-square test.

A p-value < 0.05 was considered as significant for all statistical tests. The statistical analyses were performed using R software, version 3.6.1 (R Foundation for Statistical Computing, Vienna, Austria).

The significance of each variable was assessed by univariate and multivariate COX proportional hazards model for investigating the independent high-risk factors of progression of illness with its hazard ratio (HR) and 95% confidence interval (CI). All the variables at a statistically significant level(p<0.05) after multivariate COX analysis were candidates for formulation of a nomogram, which is based on proportionally converting each multivariate regression coefficient to a 0-to 100-point scale, by using the rms package of R. The predictive performance of the nomogram was measured by concordance index (C-index) and calibration with 1000 bootstrap samples to decrease the overfit bias [10] . Clinical characteristics of the stable group and the progressive group were compared. Age, comorbidity, lymphocyte count, D-dimer, LDH were significantly different between these two groups on univariate analysis and log-rank test by Kaplan-Meier analysis ( Table 1 and supplementary table and Figure S1 ).

Further multivariate COX analysis showed that comorbidity (HR 3.9, 95%CI

1.9 -7.9) , age > 60 years (HR 3.0, 95%CI 1.4 -6.0), lymphocyte count ≤ 1.0 × 10 9 /L (HR 3.7, 95% CI 1.8 -7.8), LDH (250 -500 U/L) (HR 2.5, 95% CI 1.2 -5.2) and LDH > 500 U/L (HR 9.8, 95%CI 2.8 -33.8) were independent highrisk factors associated with progression of illness (Table 2) . CURB-65 of 208 patients were from 0 to 2 points, even for those with progression to severe disease and death, suggesting CURB-65 may not be suitable for COVID-19. A c c e p t e d M a n u s c r i p t

In order to facilitate clinical use and further assessment, a novel scoring model was established according to the results of nomogram, named as CALL (comorbidity, age, lymphocyte and LDH), which scores from 4 to 13 points (Table 3) . For lymphocyte scores, we chose the definition of lymphopenia (≤ 1.0 ×10 9 /L) as cut off. For LDH, there were 3 levels: <250 U/L, the ULN in our laboratories, >500 U/L, 2x ULN and between 250-500 U/L. ROC analysis was used to assess the performance of the CALL model, the AUROC was 0.91 (95% CI 0.86 -0.94). Using a cutoff value of 6 points, the positive predictive values (95% CI) were 50.7% ( 38.9% -62.4% ) and the negative predictive values (95% CI) were 98.5% ( 94.7% -99.8%) for prediction. Using a cutoff value of 9 points, the positive predictive values (95% CI) were 78.3% (56.3% -92.5%) and negative predictive values (95% CI) were 11.9% (7.6% -17.4%) ( Table 4) .

Furthermore, CALL scores were classified into 3 levels of risk according to their probabilities to progression, those with 4-6 points had less than 10% probabilities of progression were considered low risk (Class A), 7-9 points with 10% -40% probabilities of progression were intermediate risk (class B), and 10-13 points with over 50% probabilities were high risk (Class C) (supplementary Figure S2 ).

The rapidly increasing number of new COVID-19 cases daily worldwide has put a heavy burden on the medical resources in countries with large outbreaks. Therefore, identifying risk factors at presentation that predict the likelihood of disease progression would help the physicians to decide which group of patients can be managed safely at district hospitals and who needs early transfer to tertiary centers. Age, comorbidities, lymphopenia, serum ferritin, d-dimer levels, cardiac troponin I, lactate dehydrogenase, IL-6, subsets had been shown to be associated with poor prognosis and increased A c c e p t e d M a n u s c r i p t mortalities [4] [5] [6] [11] [12] [13] . Guan et al [14] described the clinical characteristics of 1,099 patients with laboratory-confirmed COVID-19 from 552 hospitals through 29 January 2020. Lymphopenia was observed in 82.1% of patients.

Oxygen saturation, respiratory rate, blood leukocyte/lymphocyte count and chest X-ray/CT manifestations predicted poor clinical outcomes. Increasing age and comorbidities were associated disease. Severe cases had more prominent laboratory abnormalities (i.e., leukopenia, lymphopenia, thrombocytopenia, elevated C-reactive protein levels) as compared with nonsevere cases. Zhou et al [15] showed that older age, high SOFA score, and ddimer greater than 1 µg/L are potential risk factors that could help clinicians to identify patients with poor prognosis at an early stage.

Here, we derived a risk factors scoring system (CALL) based on patients' age, comorbidities, lymphocyte count and serum LDH at presentation could identify a group of patients with low risk of disease progression. Over 96% of subjects with CALL score of 4-6 points will not progress to severe disease. In our cohorts of 208 patients, 133 (63.9%) had 4-6 points (class A), including patients age > 60 but without comorbidities, these patients could be safely managed at peripheral or district hospitals. On the other hand, some patients age < 60 without comorbidities, might benefit from early transfer to tertiary centers if they had markedly elevated LDH and severe lymphopenia (7 or more points). The CALL scoring system with 4 clinical parameters is also simpler than the 12 parameters MuLBSTA score proposed by Guo L et al [16] .

Our study has several limitations. Firstly, the sample size is still small, it involved only patients in 2 centers outside Hubei and may not be applicable to the patients in Wuhan or Hubei. Secondly, a prospective study is needed to confirmed the reliability of the CALL model. Finally, adding other specific markers might further improve the sensitivity and specificity.

In summary, the four clinical parameters in CALL model with its high accuracy and easy-to-use features achieved an optimal prediction of progression, and can be easily tested in clinical cohorts in countries or regions A c c e p t e d M a n u s c r i p t HR was calculated comparing with comorbidity vs without comorbidity, lymphocyte ≤ 1.0×10 9 /L vs > 1.0×10 9 /L, age≤ 60 (years) vs >60, LDH≤ 250 U/L vs LDH 250-500 U/L or> 500 U/L.

Abbreviations: HR, hazard ratio; CI, confidence interval; LDH, lactate dehydrogenase. 

Novel coronavirus(2019-nCoV): situation report-40

Evidence of SARS-CoV-2 infection in returning travelers from Wuhan, China

WHO Virtual press conference on COVID

Clinical features of patients with 2019 novel coronavirus in Wuhan, China

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China

Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected: interim guidance

National Health Commission (NHC) of the PRC and National Administration Chinese Medicine of the PRC. Guidance for Corona Virus Disease 2019: Prevention, Control, Diagnosis and Management

The CURB65 pneumonia severity score outperforms generic sepsis and early warning scores in predicting mortality in community-acquired pneumonia

Towards better clinical prediction models: seven steps for development and an ABCD for validation

Clinical Characteristics of Imported Cases of COVID-19 in Jiangsu Province: A Multicenter Descriptive Study

Clinical Course and Outcomes of Critically Ill Patients With SARS-CoV-2 Pneumonia in Wuhan, China: A Single-Centered, Retrospective, Observational Study

Clinical Characteristics Predicting Progression of COVID-19 (2/17/2020)

Clinical Characteristics of Coronavirus Disease 2019 in China

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Clinical features predicting mortality risk in patients with viral pneumonia: The MuLBSTA Score. Front Microbiol